VILDAGLIPTIN

VILDAGLIPTIN

Application

Vildagliptin has been used:as a dipeptidyl peptidase-4 (DPP4) inhibitor to study its effects on endoplasmic reticulum (ER) pathway under diabetic conditionsin pharmacological inhibition to investigate the kinetics of transposable element (TE) desilencing and confirm its dependence on DPF-3 (a P-granule-localized N-terminal dipeptidase) enzymatic activityto study its electrochemical properties and determinationin biological fluid and drug forms

Biochem/physiol Actions

Vildagliptin ia a selective inhibitor of dipeptidyl peptidase 4 (DPP4). This enzyme breaks down the incretins GLP-1 and GIP, gastrointestinal hormones that are released in response to a meal. By preventing GLP-1 and GIP inactivation, GLP-1 and GIP are able to potentiate the secretion of insulin and suppress the release of glucagon by the pancreas.

Vildagliptin may participate in lipid metabolism. It plays a key role in attenuating postprandial hypertriglyceridemia, reducing serum triglycerides, apolipoprotein B, and blood total cholesterol levels. Vildagliptin is used in diabetes mellitus type 2 (DM2) therapy and may also possess vasculoprotective properties. Vildagliptin also helps to improve mitochondrial dysfunction caused by diabetes.

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour InChI key InChI Manufacturer Solubility Form Assay Price Quantity
3576117 VILDAGLIPTIN white to beige SYOKIDBDQMKNDQ-NHMCJKAESA-N 1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12-,13+,14-,16+,17-/m0/s1 SIGMA-ALDRICH
£392.79 (exc VAT) per 250MG
-
+
3576118 VILDAGLIPTIN white to beige SYOKIDBDQMKNDQ-NHMCJKAESA-N 1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12-,13+,14-,16+,17-/m0/s1 SIGMA-ALDRICH
£100.98 (exc VAT) per 50MG
-
+